Online inquiry

IVTScrip™ mRNA-Anti-IL6&IL6R, FE 999301(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7112MR)

This product GTTS-WQ7112MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets IL6&IL6R gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000600.5; NM_000565.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3569; 3570
UniProt ID P05231; P08887
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL6&IL6R, FE 999301(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ7112MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14213MR IVTScrip™ mRNA-Anti-IL17A, RG4934(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA RG4934
GTTS-WQ3872MR IVTScrip™ mRNA-Anti-IL6R, BCD-089(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BCD-089
GTTS-WQ781MR IVTScrip™ mRNA-Anti-AXL, Ab-2(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA Ab-2
GTTS-WQ6375MR IVTScrip™ mRNA-Anti-Factor IX substitute, CSL654(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CSL654
GTTS-WQ10714MR IVTScrip™ mRNA-Anti-ALB&IL17A, M-1095(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA M-1095
GTTS-WQ1187MR IVTScrip™ mRNA-Anti-ERBB2, ABP 980(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABP 980
GTTS-WQ4160MR IVTScrip™ mRNA-Anti-PDCD1, BI-754091(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BI-754091
GTTS-WQ7671MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, GEN3013(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GEN3013
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW